🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 23 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 24/10/2011 | 41,62 | 44,04 | 40,45 | 44,01 | +5,44% | 8,63% | 3.309.800 |
| 21/10/2011 | 42,31 | 43,16 | 40,45 | 41,74 | -1,28% | 6,41% | 3.850.800 |
| 20/10/2011 | 40,27 | 42,65 | 39,87 | 42,28 | +5,25% | 6,90% | 2.873.200 |
| 19/10/2011 | 41,10 | 41,32 | 40,05 | 40,17 | -1,88% | 3,09% | 1.559.600 |
| 18/10/2011 | 40,12 | 41,44 | 40,09 | 40,94 | +2,12% | 3,36% | 2.216.400 |
| 17/10/2011 | 41,50 | 42,85 | 39,37 | 40,09 | -7,37% | 8,39% | 6.482.200 |
| 14/10/2011 | 43,81 | 43,81 | 41,55 | 43,28 | -1,37% | 5,16% | 3.827.500 |
| 13/10/2011 | 43,88 | 44,20 | 42,50 | 43,88 | +9,05% | 3,87% | 7.828.200 |
| 12/10/2011 | 40,70 | 41,10 | 38,55 | 40,24 | +0,73% | 6,27% | 4.711.600 |
| 11/10/2011 | 40,41 | 41,36 | 37,27 | 39,95 | -1,14% | 10,12% | 8.658.200 |
| 10/10/2011 | 44,00 | 44,05 | 39,94 | 40,41 | -9,07% | 9,34% | 5.239.800 |
| 07/10/2011 | 44,53 | 45,24 | 43,26 | 44,44 | -0,43% | 4,45% | 1.914.700 |
| 06/10/2011 | 45,01 | 45,19 | 43,72 | 44,63 | -1,09% | 3,27% | 1.499.000 |
| 05/10/2011 | 43,49 | 45,26 | 42,53 | 45,12 | +4,23% | 6,28% | 2.696.100 |
| 04/10/2011 | 40,63 | 43,45 | 40,34 | 43,29 | +6,92% | 7,65% | 3.690.000 |
| 03/10/2011 | 44,28 | 44,28 | 40,08 | 40,49 | -8,93% | 9,49% | 3.472.800 |
| 30/09/2011 | 43,91 | 45,44 | 43,70 | 44,46 | -0,11% | 3,96% | 2.615.300 |
| 29/09/2011 | 46,45 | 46,85 | 43,36 | 44,51 | -2,58% | 7,51% | 1.927.800 |
| 28/09/2011 | 47,79 | 47,91 | 45,51 | 45,69 | -4,21% | 5,02% | 1.990.200 |
| 27/09/2011 | 49,28 | 50,06 | 47,39 | 47,70 | -2,41% | 5,42% | 2.230.800 |
| 26/09/2011 | 50,80 | 51,15 | 46,69 | 48,88 | -3,65% | 8,78% | 2.518.000 |
| 23/09/2011 | 48,98 | 51,05 | 48,86 | 50,73 | +2,88% | 4,47% | 2.523.000 |
| 22/09/2011 | 51,48 | 51,98 | 47,96 | 49,31 | -7,28% | 7,81% | 4.076.800 |
| 21/09/2011 | 51,98 | 54,38 | 51,52 | 53,18 | +2,17% | 5,50% | 2.628.000 |
| 20/09/2011 | 50,36 | 52,86 | 50,01 | 52,05 | +3,73% | 5,66% | 3.443.900 |
| 19/09/2011 | 49,78 | 50,79 | 48,45 | 50,18 | -0,67% | 4,70% | 1.882.300 |
| 16/09/2011 | 50,30 | 51,11 | 50,03 | 50,52 | +0,80% | 2,15% | 2.211.600 |
| 15/09/2011 | 51,06 | 51,17 | 49,73 | 50,12 | -0,85% | 2,82% | 2.744.100 |
| 14/09/2011 | 50,23 | 51,17 | 49,50 | 50,55 | +0,68% | 3,32% | 2.158.200 |
| 13/09/2011 | 47,98 | 50,47 | 47,53 | 50,21 | +5,09% | 6,13% | 2.916.000 |